Kidney dialysis drug study pulled before it started
NCT ID NCT02695641
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study was designed to see how a low dose of bevacizumab (Avastin) behaves in the body and whether it safely lowers a certain protein (VEGF-A) in people with kidney failure on dialysis. The goal was to gather information for a future trial on preventing dialysis access failure. However, the study was withdrawn before any participants were enrolled, so no data were collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bevacizumab (Avastin)
What this could lead to
If successful, this could help design a future trial to prevent dialysis access failure.
What could go wrong
The study was withdrawn before enrolling anyone, so no results exist. Even if it had run, it was a tiny early-phase trial focused on drug levels, not on patient outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.